Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
Study sponsor: Recursion Pharmaceuticals Inc. · RXRX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-08-18Actual
Enrollment · participants25Actual
Source updated2026-08-17Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.